| |
|
Rituximab (MabThera, Roche Products) will now be routinely available to certain NHS patients with chronic lymphocytic leukaemia, thanks to final guidance published today (28 July). The NHS has three months to begin implementing this new guidance... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - Wednesday, July 28, 2010
|
|
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - Sunday, July 25, 2010
|
|
Authors: Joan H Admirand, Ronald J Knoblock, Kevin R Coombes, Constantine Tam, Ellen J Schlette, William G Wierda, Alessandra Ferrajoli, Susan O'Brien, Michael J Keating, Rajyalakshmi Luthra, L Jeffrey Medeiros
& Lynne V Abruzzo (Source: Modern Pathology AOP)
Source: Modern Pathology AOP - Thursday, July 22, 2010
|
|
In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment. (Source: British Journal of Haematology)
Source: British Journal of Haematology - Wednesday, July 21, 2010
|
|
Authors: M Russo, C Spagnuolo, S Volpe, A Mupo, I Tedesco
& G-L Russo (Source: British Journal of Cancer AOP)
Source: British Journal of Cancer AOP - Monday, July 19, 2010
|